• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

X-trodes’ Smart Skin Earns FDA Clearance for Home-Based Electrophysiological Monitoring

by Fred Pennic 02/20/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
X-trodes' Smart Skin Earns FDA Clearance for Home-Based Electrophysiological Monitoring

What You Should Know:

– X-trodes, a pioneer in wireless monitoring solutions, has achieved a major milestone with the U.S. Food and Drug Administration (FDA) granting 510(k) clearance for its Smart Skin solution, marketed as the X-trodes System M.

– The FDA clearance positions X-trodes as a frontrunner in democratizing advanced electrophysiological monitoring. By bringing clinical-grade technology to the home environment, X-trodes paves the way for personalized healthcare solutions, empowering individuals to actively participate in their health management.

What is Smart Skin?

Smart Skin is a wireless, multi-modal electrode patch designed to monitor various biopotential signals from anywhere on the body. It captures data on:

– Brain activity (EEG)

– Cardiac function (EKG/ECG)

– Eye movements (EOG)

– Muscle activity (EMG)

The discreet and comfortable patches require no gels, wires, or messy solutions, making them ideal for continuous monitoring in everyday settings.

Transforming Electrophysiological Monitoring

Historically, electrophysiological monitoring confined patients to clinical settings with cumbersome equipment. X-trodes’ Smart Skin disrupts this paradigm by transforming an entire monitoring lab into a discreet, flexible, and entirely wireless patch. This empowers users with continuous, medical-grade monitoring in their daily lives, fostering personalized healthcare management in various conditions.

X-trodes’ technology rests on over 15 years of research led by Prof. Yael Hanein at Tel Aviv University’s neuroengineering lab. Numerous peer-reviewed studies published in prestigious journals like Nature Scientific Reports and the Journal of Neural Engineering validate its efficacy.

“The X-trodes system is the next generation of wearable and fully wireless solutions, enabling clinicians and researchers to unleash the full potential of medical-grade electrophysiological monitoring,” said Ziv Peremen, PhD, CEO of X-trodes. “Gaining FDA clearance affirms the value of this technology and its potential to improve health and wellness through access to real-time electrophysiological data. It will further shorten the path to commercialization for a range of clinical use cases.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: FDA Clearance

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication

Most-Read

Oracle Lays Off 539 Kansas City Employees as Focus Shifts to AI Data Centers

Oracle Lays Off 539 Kansas City Employees as Focus Shifts to AI Data Centers

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

HHS Reverses 2024 Tech Reorganization: Why HHS Just Stripped AI and Cyber Operations Out of the ONC

How Small Medical Practices Can Build HIPAA-Aligned DevSecOps Without Enterprise Budgets

How Small Medical Practices Can Build HIPAA-Aligned DevSecOps Without Enterprise Budgets

Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration

Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration

Microsoft Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Microsoft Launches Copilot Health, Integrates Apple Health, Oura, and 50,000 EHRs in New AI Push

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

RadNet Subsidiary DeepHealth Acquires French Radiology AI Leader Gleamer

RadNet’s $269M AI Play: DeepHealth Acquires French AI Gleamer

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

The "Platform" Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

The “Platform” Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |